M1巨噬细胞外泌体miR-132-3p介导SLE弥漫性肺泡出血
该研究在降植烷诱导的SLE-DAH小鼠模型及人肺泡上皮A549细胞和肺微血管内皮HPMECs中,探讨M1巨噬细胞来源外泌体miR-132-3p的作用。结果显示miR-132-3p通过靶向SIRT1/NF-κB轴损害肺泡屏障完整性并增强炎症信号,miR-132-3p拮抗剂可减轻小鼠肺部出血和炎症。
要点
- SLE-DAH小鼠模型中miR-132-3p拮抗剂减轻肺出血、肺泡损伤及BALF炎症因子升高。
- miR-132-3p过表达下调ZO-1、Occludin、E-cadherin并降低TEER、增加FITC-葡聚糖通透性。
- 双荧光素酶实验证实miR-132-3p与SIRT1直接互作,抑制SIRT1并增强NF-κB p65和IκBα磷酸化。
核心结论
- M1巨噬细胞来源外泌体miR-132-3p通过损害肺泡屏障完整性和经SIRT1/NF-κB轴增强炎症信号促进SLE相关DAH肺损伤。
- 靶向miR-132-3p可能为SLE-DAH提供新的治疗选择。
研究设计与样本
- 建立降植烷诱导的SLE-DAH小鼠模型,给予miR-132-3p拮抗剂或对照。
- 体外使用人肺泡上皮A549细胞和人肺微血管内皮细胞HPMECs,分别转染miR-132-3p模拟物或抑制剂。
- 采用qRT-PCR、western blotting、免疫荧光、TEER测定、FITC-葡聚糖通透性、TUNEL assay和双荧光素酶实验评估屏障完整性、炎症、凋亡及分子信号。
主要发现
- 与对照相比,降植烷诱导的SLE-DAH小鼠出现明显肺出血、肺重量增加和肺泡损伤,BALF中IL-6、TNF-α、IL-1β升高而IL-10、TGF-β降低,miR-132-3p拮抗剂可减轻这些变化。
- 两种模型中miR-132-3p在M1巨噬细胞、外泌体及受体A549和HPMEC细胞中上调,并被拮抗剂或抑制剂抑制。
- miR-132-3p过表达通过下调ZO-1、Occludin和E-cadherin及TEER损害屏障完整性,增强FITC-葡聚糖通透性并促进凋亡,抑制miR-132-3p后均逆转。
- miR-132-3p过表达时SIRT1受抑制、NF-κB p65和IκBα磷酸化增强,双荧光素酶实验证实miR-132-3p与SIRT1直接互作。
临床怎么用
- 原文提出靶向miR-132-3p可能为SLE-DAH提供新的治疗选择。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: This study examines how exosomal miR-132-3p from M1 macrophages contributes to the development of SLE-associated diffuse alveolar haemorrhage (SLE-DAH) and the molecular mechanisms involved. METHODS: A pristane-induced murine model of SLE-DAH was established, and mice received either a miR-132-3p antagomir or control. Parallel in vitro studies were conducted using human alveolar epithelial (A549) and human pulmonary microvascular endothelial cells (HPMECs) undergoing treatment with either miR-132-3p mimics or inhibitors. Barrier integrity, inflammation, apoptosis and molecular signalling were evaluated using real-time PCR (qRT-PCR), western blotting, immunofluorescence, transepithelial electrical resistance (TEER) measurement, FITC-dextran permeability, TUNEL assay and dual-luciferase assays. RESULTS: Compared with controls, pristane-induced SLE-DAH mice exhibited pronounced pulmonary haemorrhage, lung weight gain and alveolar damage, along with elevated inflammation-related cytokines (IL-6, TNF-α, IL-1β) and decreased immune-regulating mediators (IL-10, TGF-β) in bronchoalveolar lavage fluid; these changes were alleviated by miR-132-3p antagomir. miR-132-3p was upregulated in M1 macrophages, exosomes, and recipient A549 and HPMEC cells in both models, and suppressed by antagomir or inhibitor. Its overexpression impaired barrier integrity by downregulating ZO-1, Occludin and E-cadherin, TEER, enhanced FITC-dextran permeability and promoted apoptosis; all were reversed upon miR-132-3p inhibition. Meanwhile, SIRT1 was suppressed and NF-κB p65 and IκBα phosphorylation enhanced, with dual-luciferase assays confirming the direct interaction between miR-132-3p and SIRT1. CONCLUSION: M1 macrophage-originated exosomal miR-132-3p promotes lung injury in SLE-associated DAH by impairing alveolar barrier integrity and enhancing inflammatory signalling via the SIRT1/NF-κB axis. Targeting miR-132-3p could offer a novel treatment option for SLE-DAH.
引用
- Chen X, Xie J, Lu F, et al. Exosomal miR-132-3p derived from M1 macrophages mediates diffuse alveolar haemorrhage in systemic lupus erythematosus. Rheumatology (Oxford). 2026. PMID: 41208037. doi:10.1093/rheumatology/keaf600
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。